- Home
- TERN vs PACB Comparison
TERN vs PACB Comparison
Compare TERN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- PACB
- Stock Information
- Founded
- TERN 2017
- PACB 2000
- Country
- TERN United States
- PACB United States
- Employees
- TERN N/A
- PACB N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- TERN Health Care
- PACB Industrials
- Exchange
- TERN Nasdaq
- PACB Nasdaq
- Market Cap
- TERN 495.2M
- PACB 462.1M
- IPO Year
- TERN 2021
- PACB 2010
- Fundamental
- Price
- TERN $7.06
- PACB $1.30
- Analyst Decision
- TERN Buy
- PACB Buy
- Analyst Count
- TERN 5
- PACB 8
- Target Price
- TERN $15.63
- PACB $1.91
- AVG Volume (30 Days)
- TERN 1.0M
- PACB 8.6M
- Earning Date
- TERN 08-05-2025
- PACB 08-07-2025
- Dividend Yield
- TERN N/A
- PACB N/A
- EPS Growth
- TERN N/A
- PACB N/A
- EPS
- TERN N/A
- PACB N/A
- Revenue
- TERN N/A
- PACB $156,110,000.00
- Revenue This Year
- TERN N/A
- PACB $3.36
- Revenue Next Year
- TERN N/A
- PACB $18.20
- P/E Ratio
- TERN N/A
- PACB N/A
- Revenue Growth
- TERN N/A
- PACB N/A
- 52 Week Low
- TERN $1.87
- PACB $0.85
- 52 Week High
- TERN $11.40
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- TERN 71.76
- PACB 45.92
- Support Level
- TERN $6.43
- PACB $1.19
- Resistance Level
- TERN $6.34
- PACB $1.36
- Average True Range (ATR)
- TERN 0.42
- PACB 0.13
- MACD
- TERN 0.04
- PACB -0.03
- Stochastic Oscillator
- TERN 98.68
- PACB 22.22
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.